Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/48639
EVALUATION OF ELISA-BASED MULTIPLEX PEPTIDES FOR THE DETECTION OF HUMAN SERUM ANTIBODIES INDUCED BY ZIKA VIRUS INFECTION ACROSS VARIOUS COUNTRIES
Author
Viedma, Maria del Pilar Martinez
Panossian, Stephen
Gifford, Kennedy
García, Kimberly
Figueroa, Isis
Parham, Leda
Moraes, Laise de
Gomes, Lillian Nunes
Salum, Tamara García
Perret, Cecilia
Weiskopf, Daniela
Tan, Gene S.
Silva, Antônio Augusto
Oliveira, Viviane Sampaio Boaventura de
Palacios, Guillermo M. Ruiz-
Sette, Alessandro
Silva, Aruna Dharshan de
Medina, Rafael A.
Lorenzana, Ivette
Akrami, Kevan M.
Cunha, Antonio Ricardo Khouri
Olson, Daniel
Pickett, Brett E.
Panossian, Stephen
Gifford, Kennedy
García, Kimberly
Figueroa, Isis
Parham, Leda
Moraes, Laise de
Gomes, Lillian Nunes
Salum, Tamara García
Perret, Cecilia
Weiskopf, Daniela
Tan, Gene S.
Silva, Antônio Augusto
Oliveira, Viviane Sampaio Boaventura de
Palacios, Guillermo M. Ruiz-
Sette, Alessandro
Silva, Aruna Dharshan de
Medina, Rafael A.
Lorenzana, Ivette
Akrami, Kevan M.
Cunha, Antonio Ricardo Khouri
Olson, Daniel
Pickett, Brett E.
Affilliation
"Múltipla ver em Notas"
Abstract
Zika virus (ZIKV) is a mosquito-borne Flavivirus with a positive-sense RNA genome, which
are generally transmitted through the bite of an infected Aedes mosquito. ZIKV infections could be
associated with neurological sequelae that, and otherwise produces similar clinical symptoms as other
co-circulating pathogens. Past infection with one member of the Flavivirus genus often induces crossreactive
antibodies against other flaviruses. These attributes complicate the ability to differentially
diagnose ZIKV infection from other endemic mosquito-borne viruses, making it both a public health
issue as well as a diagnostic challenge. We report the results from serological analyses using arbovirusspecific
peptides on 339 samples that were previously collected from 6 countries. Overall, we found
that our multiplexed peptide-based ELISA was highly efficient for identifying ZIKV antibodies as
early as 2 weeks post infection, and that it correlates with microneutralization, plaque reduction
neutralization tests (PRNTs) and commercial tests for ZIKV in previously characterized samples. We
observed that seropositivity varied by patient cohort, reflecting the sampling period in relation to the 2015–2016 ZIKV outbreak. This work evaluates the accuracy, specificity, and sensitivity of our
peptide-based ELISA method for detecting ZIKV antibodies from geographically diverse regions.
These findings can contribute to ongoing serological methods development and can be adapted for
use in future studies.
Share